Search Results - subject:"Irritable bowel syndrome"

Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland

Fisher, Mark; Walker, Andrew; Falqués, Meritxell; … - In: The European journal of health economics : HEPAC ; … 17 (2016) 9, pp. 1091-1100

Persistent link: https://www.econbiz.de/10011660226

Konzepte der Kalkulation direkter und indirekter Kosten im Rahmen gesundheitsökonomischer Evaluationen

Prenzler, Anne - 2010

Persistent link: https://www.econbiz.de/10008798477

Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information

Mohseninejad, Leyla; Feenstra, Talitha; Horst, Henriëtte; … - In: The European Journal of Health Economics 14 (2013) 6, pp. 947-957

Screening patients with IBS-D or IBS-mix for CD is almost certainly cost-effective. The screening program would improve the quality of life of those patients with IBS symptoms who actually have CD at a relatively low cost. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2013

Persistent link: https://www.econbiz.de/10010993929

Costs of Irritable Bowel Syndrome in the UK and US

Maxion-Bergemann, Stefanie; Thielecke, Frank; Abel, Florian - In: PharmacoEconomics 24 (2006) 1, pp. 21-37

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, with an estimated …

Persistent link: https://www.econbiz.de/10005449183

Patients Diagnosed with Irritable Bowel Syndrome: Medical Record Validation of a Claims-Based Identification Algorithm

Legorreta, Antonio P.; Ricci, Jean-Francois; Markowitz, Mike - In: Disease Management and Health Outcomes 10 (2002) 11, pp. 715-722

code description was revised to `irritable bowel syndrome'. Results: The PPVs of end nodes of the tree varied (18 to 100 …Objective: This study developed and validated a claims-based algorithm for identifying patients with irritable bowel … syndrome (IBS) and investigated the characteristics of patients associated with a correct identification. Methods: Using a …

Persistent link: https://www.econbiz.de/10005590195

Burden of Illness in Irritable Bowel Syndrome Comparing Rome I and Rome II Criteria

Badia, Xavier; Mearin, Fermin; Balboa, Agustin; Baro, Eva; … - In: PharmacoEconomics 20 (2002) 11, pp. 749-758

Objectives: To evaluate the burden of illness in irritable bowel syndrome (IBS), in terms of resource utilisation …

Persistent link: https://www.econbiz.de/10005243189

Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies: A Review and Synthesis of the Literature

Rentz, Anne M.; Battista, Carmelina; Trudeau, Elyse; … - In: PharmacoEconomics 19 (2001) 4, pp. 349-363

gastroesophageal reflux disease and dyspepsia, with a growing interest in irritable bowel syndrome but little research in gastroparesis …

Persistent link: https://www.econbiz.de/10005590409

Quality of Life in Irritable Bowel Syndrome

Lea, Richard; Whorwell, Peter J. - In: PharmacoEconomics 19 (2001) 6, pp. 643-653

effect of therapy. This is particularly so for irritable bowel syndrome (IBS) where there is often a tendency for a chronic …. Several disease-specific instruments [Irritable Bowel Syndrome Quality of Life (IBS-QOL, IBSQOL) and Functional Digestive …

Persistent link: https://www.econbiz.de/10005449241

Economic Burden of Irritable Bowel Syndrome: Proposed Strategies to Control Expenditures

Camilleri, Michael; Williams, Donald E. - In: PharmacoEconomics 17 (2000) 4, pp. 331-338

It has been suggested that the annual direct costs for irritable bowel syndrome (IBS) are now around $US41 billion in …

Persistent link: https://www.econbiz.de/10005590450